Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hagai Tavori

Showing results (1-10 of 58) with videos related to

Pageof 6
Sort By:
Vascular Health and Risk Management|September 9, 2015
New developments in atherosclerosis: clinical potential of PCSK9 inhibitionIlaria Giunzioni, Hagai Tavori
Circulation Research|August 16, 2014
Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shotSergio Fazio, Hagai Tavori
Atherosclerosis|December 30, 2014
On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effectsHagai Tavori, Shirya Rashid, Sergio Fazio
Advances in Experimental Medicine and Biology|March 12, 2010
Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activityHagai Tavori, Jacob Vaya, Michael Aviram
Expert Review of Cardiovascular Therapy|September 23, 2014
Alirocumab: PCSK9 inhibitor for LDL cholesterol reductionHagai Tavori, Michelle Melone, Shirya Rashid
Current Opinion in Endocrinology, Diabetes, and Obesity|February 19, 2015
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9Hagai Tavori, Ilaria Giunzioni, Sergio Fazio
Current Atherosclerosis Reports|February 26, 2015
Targeting PCSK9 for therapeutic gainsMichael D Shapiro, Sergio Fazio, Hagai Tavori
Circulation Research|May 12, 2018
PCSK9: From Basic Science Discoveries to Clinical TrialsMichael D Shapiro, Hagai Tavori, Sergio Fazio
Chemistry and Physics of Lipids|April 26, 2011
Oxysterols formation as a reflection of biochemical pathways: summary of in vitro and in vivo studiesJacob Vaya, Andrea Szuchman, Hagai Tavori, et al.
Bioorganic & Medicinal Chemistry|June 24, 2008
Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activityHagai Tavori, Soliman Khatib, Michael Aviram, et al.
Pageof 6

Showing results (1-10 of 58) with videos related to

Sort By:
Pageof 6
Vascular Health and Risk Management|September 9, 2015
New developments in atherosclerosis: clinical potential of PCSK9 inhibitionIlaria Giunzioni, Hagai Tavori
Circulation Research|August 16, 2014
Peeking into a cool future: genome editing to delete PCSK9 and control hypercholesterolemia in a single shotSergio Fazio, Hagai Tavori
Atherosclerosis|December 30, 2014
On the function and homeostasis of PCSK9: reciprocal interaction with LDLR and additional lipid effectsHagai Tavori, Shirya Rashid, Sergio Fazio
Advances in Experimental Medicine and Biology|March 12, 2010
Paraoxonase 1 attenuates human plaque atherogenicity: relevance to the enzyme lactonase activityHagai Tavori, Jacob Vaya, Michael Aviram
Expert Review of Cardiovascular Therapy|September 23, 2014
Alirocumab: PCSK9 inhibitor for LDL cholesterol reductionHagai Tavori, Michelle Melone, Shirya Rashid
Current Opinion in Endocrinology, Diabetes, and Obesity|February 19, 2015
PCSK9 inhibition to reduce cardiovascular disease risk: recent findings from the biology of PCSK9Hagai Tavori, Ilaria Giunzioni, Sergio Fazio
Current Atherosclerosis Reports|February 26, 2015
Targeting PCSK9 for therapeutic gainsMichael D Shapiro, Sergio Fazio, Hagai Tavori
Circulation Research|May 12, 2018
PCSK9: From Basic Science Discoveries to Clinical TrialsMichael D Shapiro, Hagai Tavori, Sergio Fazio
Chemistry and Physics of Lipids|April 26, 2011
Oxysterols formation as a reflection of biochemical pathways: summary of in vitro and in vivo studiesJacob Vaya, Andrea Szuchman, Hagai Tavori, et al.
Bioorganic & Medicinal Chemistry|June 24, 2008
Characterization of the PON1 active site using modeling simulation, in relation to PON1 lactonase activityHagai Tavori, Soliman Khatib, Michael Aviram, et al.
Pageof 6